Compare ARK Genomic Revolution ETF (ARKG) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Canadian Natural Resources Ltd. — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while Canadian Natural Resources Ltd. trades at $47.64 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. pays a 3.73% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Canadian Natural Resources Ltd. nearer its low. Which is the better fit depends on your goals.
| ARKG | CNQ | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $44.55 | $50.55 |
52-Week Low | $24.02 | $29.31 |
Market Cap | — | $98.11B |
Enterprise Value | — | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Canadian Natural Resources (CNQ) trades at $47.65, up 0.85% with strong technical momentum. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.53 versus $1.43 expected, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 11.82 and EV/EBITDA of 6.35, while profitability metrics impress with 26.69% ROE and 22.87% net margin. Recent news highlights record production and dividend consistency.
CNQ presents a compelling investment case with strong operational performance, attractive valuation, and shareholder returns through dividends. The primary risks include oil price volatility and execution challenges in capital projects. Analyst consensus remains strongly bullish with 27 buy ratings and no sell recommendations, supporting upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
